News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
744,091 Results
Type
Article (43971)
Company Profile (317)
Press Release (699788)
Multimedia
Podcasts (120)
Webinars (20)
Section
Business (211037)
Career Advice (2118)
Deals (36767)
Drug Delivery (129)
Drug Development (83474)
Employer Resources (177)
FDA (16864)
Job Trends (15515)
News (357518)
Policy (34157)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2619)
Accelerated approval (38)
Adcomms (26)
Allergies (160)
Alliances (51588)
ALS (182)
Alzheimer's disease (1708)
Antibody-drug conjugate (ADC) (346)
Approvals (17140)
Artificial intelligence (571)
Autoimmune disease (179)
Automation (45)
Bankruptcy (372)
Best Places to Work (11770)
BIOSECURE Act (21)
Biosimilars (202)
Biotechnology (189)
Bladder cancer (167)
Brain cancer (64)
Breast cancer (664)
Cancer (5091)
Cardiovascular disease (438)
Career advice (1798)
Career pathing (39)
CAR-T (292)
CDC (53)
Celiac Disease (2)
Cell therapy (779)
Cervical cancer (39)
Clinical research (71436)
Collaboration (1841)
Company closure (4)
Compensation (1219)
Complete response letters (70)
COVID-19 (2797)
CRISPR (105)
C-suite (928)
Cystic fibrosis (150)
Data (6576)
Decentralized trials (2)
Denatured (36)
Depression (144)
Diabetes (520)
Diagnostics (6842)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (275)
Drug pricing (207)
Drug shortages (31)
Duchenne muscular dystrophy (243)
Earnings (92337)
Editorial (61)
Employer branding (22)
Employer resources (156)
Events (120813)
Executive appointments (1024)
FDA (20131)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (12)
Frontotemporal dementia (25)
Funding (1549)
Gene editing (216)
Generative AI (46)
Gene therapy (645)
GLP-1 (1033)
Government (4827)
Grass and pollen (7)
Guidances (386)
Healthcare (19084)
HIV (68)
Huntington's disease (51)
IgA nephropathy (87)
Immunology and inflammation (274)
Immuno-oncology (67)
Indications (135)
Infectious disease (3083)
Inflammatory bowel disease (204)
Inflation Reduction Act (14)
Influenza (123)
Intellectual property (263)
Interviews (329)
IPO (16926)
IRA (57)
Job creations (4075)
Job search strategy (1505)
JPM (65)
Kidney cancer (18)
Labor market (89)
Layoffs (578)
Leadership (35)
Legal (8431)
Liver cancer (95)
Longevity (21)
Lung cancer (679)
Lymphoma (389)
Machine learning (47)
Management (60)
Manufacturing (868)
MASH (175)
Medical device (13892)
Medtech (13956)
Mergers & acquisitions (20951)
Metabolic disorders (1352)
mRNA (174)
Multiple sclerosis (170)
NASH (17)
Neurodegenerative disease (345)
Neuropsychiatric disorders (94)
Neuroscience (3036)
Neurotech (1)
NextGen: Class of 2026 (6649)
Non-profit (4568)
Now hiring (70)
Obesity (643)
Opinion (295)
Ovarian cancer (173)
Pain (231)
Pancreatic cancer (243)
Parkinson's disease (298)
Partnered (34)
Patents (529)
Patient recruitment (536)
Peanut (63)
People (61068)
Pharmaceutical (88)
Pharmacy benefit managers (32)
Phase 1 (22169)
Phase 2 (31413)
Phase 3 (23541)
Pipeline (6093)
Policy (312)
Postmarket research (2655)
Preclinical (9412)
Press Release (68)
Prostate cancer (258)
Psychedelics (51)
Radiopharmaceuticals (299)
Rare diseases (941)
Real estate (6309)
Recruiting (73)
Regulatory (25608)
Reports (53)
Research institute (2449)
Resumes & cover letters (363)
Rett syndrome (30)
RNA editing (17)
RSV (81)
Schizophrenia (160)
Series A (260)
Series B (197)
Service/supplier (11)
Sickle cell disease (105)
Special edition (25)
Spinal muscular atrophy (162)
Sponsored (43)
Startups (3770)
State (2)
Stomach cancer (19)
Supply chain (111)
Tariffs (96)
The Weekly (82)
Vaccines (1055)
Venture capital (93)
Weight loss (418)
Women's health (101)
Worklife (19)
Date
Today (16)
Last 7 days (724)
Last 30 days (2944)
Last 365 days (30363)
2026 (5649)
2025 (30697)
2024 (35774)
2023 (40633)
2022 (51807)
2021 (56339)
2020 (54799)
2019 (47399)
2018 (35776)
2017 (33147)
2016 (32670)
2015 (38623)
2014 (32520)
2013 (27637)
2012 (29732)
2011 (30487)
2010 (28497)
Location
Africa (803)
Alabama (86)
Alaska (7)
Arizona (324)
Arkansas (15)
Asia (42240)
Australia (6769)
California (11827)
Canada (3412)
China (1176)
Colorado (497)
Connecticut (503)
Delaware (349)
Europe (90703)
Florida (1775)
Georgia (374)
Hawaii (3)
Idaho (61)
Illinois (922)
India (76)
Indiana (548)
Iowa (22)
Japan (464)
Kansas (127)
Kentucky (43)
Louisiana (34)
Maine (73)
Maryland (1438)
Massachusetts (8507)
Michigan (340)
Minnesota (648)
Mississippi (6)
Missouri (131)
Montana (33)
Nebraska (29)
Nevada (130)
New Hampshire (80)
New Jersey (3150)
New Mexico (29)
New York (3112)
North Carolina (1527)
North Dakota (8)
Northern California (5805)
Ohio (350)
Oklahoma (22)
Oregon (46)
Pennsylvania (2391)
Puerto Rico (24)
Rhode Island (49)
South America (1177)
South Carolina (70)
South Dakota (1)
Southern California (4626)
Tennessee (188)
Texas (1829)
United States (41991)
Utah (355)
Vermont (1)
Virginia (290)
Washington D.C. (80)
Washington State (955)
West Virginia (4)
Wisconsin (120)
Wyoming (2)
744,091 Results for "regeneron pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Regulatory
Regeneron Climbs Back After a Year of Regulatory, Manufacturing Misery
After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this summer—the lowest they’d been since early 2021. But they now sit higher than they did at the start of the year.
December 10, 2025
·
3 min read
·
Annalee Armstrong
Earnings
FDA Formally Rejects Regeneron’s Eylea HD Over Manufacturing Issues
Despite the rejection, analysts saw Regeneron’s use of an alternate filler for Eylea HD as a positive development, with BMO Capital Markets noting that this could signal the end of manufacturing troubles for the franchise.
October 29, 2025
·
2 min read
·
Tristan Manalac
Allergies
Regeneron’s Antibodies Block Cat and Birch Allergies With ‘Robust Activity’
Regeneron’s antibody duos significantly lowered eye itching and redness, as well as pin prick reactivity, in people with cat and birch allergies. Still, BMO Capital Markets expressed uncertainty about the assets’ “commercial potential in a highly generic market.”
September 9, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
February 24, 2026
·
19 min read
Approvals
FDA Hands Regeneron Two Eylea HD Nods in One Day
The approvals come as a pleasant surprise for Regeneron, analysts say, helping bolster the overall product profile of high-dose Eylea despite outstanding manufacturing concerns.
November 20, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Regeneron Announces Investor Conference Presentation - March 5, 2026
March 5, 2026
·
1 min read
Regulatory
Two FDA Decisions for Regeneron’s Eylea HD Delayed Into Q4
The delays, first revealed in Regeneron’s Q2 report, were chalked up to manufacturing issues at Novo Nordisk-owned plants.
August 21, 2025
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Ocular’s Hydrogel Beats Regeneron’s Eylea in Wet AMD Study, Plots Path to FDA
Following the successful late-stage study in wet age-related macular degeneration, Ocular plans to meet with the FDA to determine a regulatory path for Axpaxli.
February 17, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
February 27, 2026
·
14 min read
Press Releases
Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders
February 26, 2026
·
7 min read
1 of 74,410
Next
